Park Plaza Riverbank London Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2016



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Translational Vaccinology for Global Health (S1)


Organizer(s) Christopher L. Karp, Gagandeep Kang and Rino Rappuoli
October 25—29, 2016
Park Plaza Riverbank London • London, United Kingdom
Discounted Abstract Deadline: Jun 27, 2016
Abstract Deadline: Jul 26, 2016
Scholarship Deadline: Jun 27, 2016
Discounted Registration Deadline: Sep 8, 2016

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

Summary of Meeting:
The time required to launch new global health vaccines is too long and the late failure rate is unsustainably high. Key barriers include insufficient diversity and quality of preclinical concepts and candidates, immunobiological ignorance, and a lack of understanding of correlates or mechanisms of protection. Root causes include siloed science and linear thinking; poor integration across the discovery/development/delivery ecosystem; and slow entry and limited throughput in early human proof of concept testing. This Keystone Symposia meeting aims to bring together those pioneering novel, creative solutions to these problems of global vaccine discovery and development across the academic/biotech/product development partner/pharma spectrum.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Tuesday, October 25 with registration from 16:00 to 20:00. Conference events conclude on Saturday, October 29 with a closing plenary session and keynote address from 13:30 to 19:00, followed by a social hour and entertainment. We recommend return travel on Sunday, October 30 in order to fully experience the meeting.

TUESDAY, OCTOBER 25

16:00—20:00
Arrival and Registration

Foyer
18:30—20:00
Social Hour with Lite Bites

Plaza Foyer

WEDNESDAY, OCTOBER 26

07:30—08:30
Breakfast

Individual Hotel
08:30—11:30
Controlled Human Infection Models
Meeting has ended...abstracts no longer viewable online.

Ballroom
* Gagandeep Kang, Christian Medical College, India

Robert Sauerwein, Radboud University, Netherlands
Protection and Immune Responses in Malaria after Whole Sporozoite Immunization

Andrew J. Pollard, University of Oxford, UK
Insights into the Biology of Enteric Fever and Typhoid Vaccine Efficacy Using Experimental Human Challenge with Typhoidal Salmonellae

Coffee Break

Anna P. Durbin, Johns Hopkins Bloomberg School of Public Health, USA
The Dengue Human Infection Model: A Tool to Advance Vaccine Development and the Search for Immune Correlates of Protection

Daniela M. Ferreira, Liverpool School of Tropical Medicine, UK
Short Talk: Controlled Human Co-Infection with Live Attenuated Influenza Vaccine (LAIV) and Pneumococcus

Hedda Wardemann, German Cancer Research Center, Germany
Short Talk: Development and Clonal Evolution of Human Anti-CSP Memory B Cell Antibody Responses

11:45—13:00
Transportation to Central Hall Westminster

12:15—13:30
Light Lunch

Central Hall Westminster
13:30—15:30
Joint Session with Grand Challenges and Keystone Symposia
Meeting has ended...abstracts no longer viewable online.
UK & Global Innovations to Achieve the Sustainable Development Goals
Emcee: Chris Karp, Bill & Melinda Gates Foundation
Jeremy Farrar, Wellcome Trust
Welcome Address

Spotlight Speaker: Clare Elwell
Biomarkers of Nutrition Related Cognitive Development
Floriane Fidegnon-Edoh, Ursuline Academy

Keynote Conversation: Leadership in Science & Innovation - Good for Britain, Good for the World
Bill Gates, Bill & Melinda Gates Foundation
Opening Remarks
Moderator: Natasha Kaplinsky
Bill Gates, Bill & Melinda Gates Foundation
Minister Priti Patel, Secretary of State for International Development, UK
Sir Richard Branson, Virgin Group

Closing Remarks
Trevor Mundel, Bill & Melinda Gates Foundation
Gayle E. Smith, USAID (Video Address)

Central Hall Westminister
15:30—17:00
Networking and Welcome Mixer with Grand Challenges and Keystone Symposia

QEII Churchill
17:00—17:30
Transportation to Park Plaza Riverbank London

19:00—20:00
Social Hour with Lite Bites

Plaza Ballroom

THURSDAY, OCTOBER 27

07:30—08:30
Breakfast

Individual Hotel
08:30—11:30
Human Immune Profiling
Meeting has ended...abstracts no longer viewable online.

Ballroom
* Lynda M. Stuart, Bill & Melinda Gates Foundation, USA

Galit Alter, Ragon Institute of MGH, MIT and Harvard, USA
A Systems Level Approach to Defining Humoral Mechanisms of HIV Control

Mario Roederer, NIAID, National Institutes of Health, USA
Integrating High-Content Technologies for Cellular Analysis

Coffee Break

Beate Kampmann, Imperial College School of Medicine/MRC Gambia, UK
Correlates of Protection for Maternal Immunization: A Way Forward?

Leticia Kuri-Cervantes, Case Western Reserve University, USA
Short Talk: Immune Correlates to Butantan-DV/NIH-TV003 Dengue Vaccine

Darragh Duffy, Institut Pasteur, France
Short Talk: Milieu Interieur – Defining the Boundaries of a Healthy Immune Response through Standardized Immunophenotyping

11:30—13:30
On Own for Lunch

11:30—13:00
Poster Setup

Plaza Suite
13:00—22:00
Poster Viewing

Plaza Suite
13:30—15:30
Workshop 1: Correlates of Protection

Ballroom
* Penny M. Heaton, Bill & Melinda Gates Foundation, USA
Correlates of Protection for Vaccine Discovery and Development

Gemma Moncunill, ISGlobal, Spain
Immune Correlates Associated with RTS,S/AS01E Malaria Vaccination in a Pediatric Phase III Trial in Africa

Raquel Furtado, Albert Einstein College of Medicine, USA
Defining Novel Immune Correlates of Protection in Human Malaria Using Time-of-Flight Cytometry (CyTOF) and Antibody Functional Analyses

Robert Mauro DiFazio, University of Pittsburgh School of Medicine, USA
Serial PET-CT Imaging Predicts Vaccine Efficacy Against Tuberculosis in the Non-Human Primate Model

Sophie Rhodes, London School of Hygiene and Tropical Medicine, UK
Use of Mathematical Modelling for Dose Finding in T Cell-Mediated Vaccines

15:30—16:00
Coffee Available

Ballroom Foyer
16:00—18:30
Toward PK/PD in B Cell Vaccinology
Meeting has ended...abstracts no longer viewable online.

Ballroom
* Chris Wilson, Bill & Melinda Gates Foundation, USA

Michael G. McHeyzer-Williams, The Scripps Research Institute, USA
Reprogramming B Cell Memory

Arup K. Chakraborty, Massachusetts Institute of Technology, USA
Modeling Selection Forces during Antibody Affinity Maturation

W. Ripley Ballou, GlaxoSmithKline Vaccines, USA
Optimizing Somatic Hypermutation? An Intriguing Observation from the Clinic

John T. Schiller, National Cancer Institute, National Institutes of Health, USA
HPV VLP Vaccines: Asymtoting to a Single Dose?

Monia Bardelli, GlaxoSmithKline, Italy
Short Talk: Profiling the Molecular Mechanisms that Drive the Fate of Human B Cells in Response to Vaccination

18:30—19:30
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Plaza Suite
19:00—22:00
Poster Session 1

Plaza Suite

FRIDAY, OCTOBER 28

07:30—08:30
Breakfast

Individual Hotel
08:30—11:30
T Cells
Meeting has ended...abstracts no longer viewable online.

Ballroom
* Karen S. Anderson, Arizona State University, USA

Louis J. Picker, Oregon Health & Science University, USA
Cytomegalovirus Vectors: Exploiting Viral Control of the CD8+ T Cell Epitope Targeting

Bette Tina Marie Korber, Los Alamos National Laboratory, USA
Epigraph Vaccine Designs for Variable Pathogens

Coffee Break

D. Branch Moody, Brigham and Women's Hospital, USA
Beyond the MHC: Activation of T Cells by CD1 and M. tuberculosis Lipids

Andrew J. McMichael, Oxford University, UK
HLA-E-Restricted CD8 T Cells

Denise L. Doolan, James Cook University, Australia
Short Talk: Rational Vaccine Design against Complex Pathogens using Genomic Sequence

11:30—17:00
On Own for Lunch

11:30—13:00
Poster Setup

Plaza Suite
13:00—22:00
Poster Viewing

Plaza Suite
13:30—15:30
Workshop 2: Human Immunophenotyping

Ballroom
* Mark M. Davis, Stanford University, USA
Systems Immunology and Vaccine Development

Margherita Coccia, GlaxoSmithKline Vaccines, Belgium
Mass Cytometry Analysis of a Mosquirix™ Controlled Human Malaria Challenge Trial: A Multivariate Approach

Christine Dahlke, University Medical Center Hamburg-Eppendorf, Germany
The rVSV-Vaccine Platform: Comprehensive Analysis of Immunogenicity against Vector and Insert following rVSV-Vectored Ebola Vaccination

Tracey Day, Infectious Disease Research Institute, USA
First-in-Human Evaluation of Safety and Immunogenicity of the Tetravalent Mycobacterium tuberculosis Vaccine, ID93+GLA-SE

Florian Rubelt, Stanford University, USA
Distinctive Differences in B and T Cell Receptor Repertoire and Cell Frequencies Are Evident in Individual Immune Responses

Eita Sasaki, National Institute of Infectious Disease, Japan
Establishment of a Novel Safety Evaluating System for Vaccines and Adjuvants Using the Genes Expression Profile and Statistical Model

Gianna Triller, German Cancer Research Center, Germany
Single-Cell Analysis of Rare Memory B Cell Antibodies to Natural Human Malaria Infection

15:30—16:00
Coffee Available

Ballroom Foyer
16:00—18:45
Novel Approaches to Antigen Identification and Immunogen Design
Meeting has ended...abstracts no longer viewable online.

Ballroom
* Rino Rappuoli, GlaxoSmithKline Vaccines, Italy

Ashley J. Birkett, PATH Malaria Vaccine Initiative, USA
Development of Vaccines for Malaria Parasite Elimination and Eradication: The Role of Monoclonal Antibodies in Accelerating Development

Peter D. Kwong, NIAID, National Institutes of Health, USA
Structure-Based Design of Fusion-Glycoprotein Vaccines for Paramyxoviruses

Louis Schofield, James Cook University, Australia
Carbohydrate-Based Vaccines for Malaria

Florian Krammer, Icahn School of Medicine at Mount Sinai, USA
Towards a Universal Influenza Virus Vaccine

Masaru Kanekiyo, NIAID, National Institutes of Health, USA
Short Talk: Vaccine-Induced Broad and Potent Influenza H1N1 Neutralizing Antibody Targets a Novel Viral Site of Vulnerability in the Hemagglutinin Head Domain

Kizzmekia S. Corbett, NIAID, National Institutes of Health, USA
Short Talk: Immunogenicity of MERS Coronavirus Spike Trimer Vaccine

18:45—19:45
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Plaza Suite
19:00—22:00
Poster Session 2

Plaza Suite

SATURDAY, OCTOBER 29

07:30—08:30
Breakfast

Individual Hotel
08:30—11:30
Adjuvants, Mucosal and Otherwise
Meeting has ended...abstracts no longer viewable online.

Ballroom
* Anna P. Durbin, Johns Hopkins Bloomberg School of Public Health, USA

Gagandeep Kang, Christian Medical College, India
Mucosal Barriers to Oral Vaccination in Developing Countries

Ulrich H. Von Andrian, Harvard Medical School, USA
Induction of Mucosal Immune Responses

Coffee Break

Arnaud Marchant, Université Libre de Bruxelles, Belgium
Impact of Adjuvants on the Functional Program of Vaccine-Induced T Lymphocytes

Aideen C. Allen, Trinity College Dublin, Ireland
Short Talk: Exploiting Synergy between STING and TLR Agonists as Adjuvants for a Pertussis Vaccine

Wivine Burny, GlaxoSmithKline, Belgium
Short Talk: Early Responses to Adjuvanted Vaccination in Humans: Relationships with Adaptive Responses

11:30—13:30
On Own for Lunch

13:30—15:30
Clinical Trial Readouts
Meeting has ended...abstracts no longer viewable online.

Ballroom
* W. Ripley Ballou, GlaxoSmithKline Vaccines, USA

Carolyn E. Clark, Norwegian Institute of Public Health, Norway
The rVSV-Vectored Ebola Vaccine: Fast-tracked Clinical Testing during the 2014-15 Epidemic

Thomas Heineman, GlaxoSmithKline Vaccines, USA
Herpes Zoster Subunit Vaccine - Overcoming Immunosenescence in the Elderly

Neil Ferguson, Imperial College London, UK
Modelling the Efficacy Profile of the Sanofi Dengue Vaccine: Implications for Use

Leo Swadling, University of Oxford, UK
Short Talk: Potent Virally Vectored T-Cell Vaccines Fail to Reconstitute an Effective HCV-Specific T-Cell Response during Chronic Infection

15:30—16:00
Coffee Available

Ballroom Foyer
16:00—17:45
Accelerating Global Health Vaccine R&D
Meeting has ended...abstracts no longer viewable online.

Ballroom
* Christopher L. Karp, Bill & Melinda Gates Foundation, USA

Rino Rappuoli, GlaxoSmithKline Vaccines, Italy
Reverse Vaccinology 2.0: Human Immunology Instructs Vaccine Antigen Design

Karen S. Anderson, Arizona State University, USA
Frontiers of T Cell Epitope Prediction/Discovery for Cancer Vaccines

Rafi Ahmed, Emory University School of Medicine, USA
Antibody Repertoires in Vaccinated Populations

17:45—18:30
Closing Keynote Address
Meeting has ended...abstracts no longer viewable online.

Ballroom
Chris Wilson, Bill & Melinda Gates Foundation, USA
Collaboration Across Traditional Boundaries to Accelerate Global Health Vaccine R&D

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Plaza Suite
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Plaza Suite

SUNDAY, OCTOBER 30

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsor for generously supporting this meeting:

Bill & Melinda Gates Foundation

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional support for this conference from:

Sanofi Pasteur

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI126822-01

Funding for this conference was made possible [in part] by 1 R13 AI 126822 - 01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



GlaxoSmithKline Vaccines


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676